IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0659058
(2004-08-05)
|
등록번호 |
US-8168171
(2012-05-01)
|
국제출원번호 |
PCT/IT2004/000444
(2004-08-05)
|
§371/§102 date |
20081125
(20081125)
|
국제공개번호 |
WO2006/013588
(2006-02-09)
|
발명자
/ 주소 |
- Mogna, Giovanni
- Strozzi, Gian Paolo
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
24 인용 특허 :
5 |
초록
▼
The present invention relates to folic acid-producing bacterial strains belonging to the genus Bifidobacterium, pharmaceutical, veterinary or food formulations containing them and the use thereof. In particular, the invention relates to new bacterial strains of human origin belonging to the genus Bi
The present invention relates to folic acid-producing bacterial strains belonging to the genus Bifidobacterium, pharmaceutical, veterinary or food formulations containing them and the use thereof. In particular, the invention relates to new bacterial strains of human origin belonging to the genus Bifidobacterium, adolescentis species (2), the genus Bifidobacterium, breve species (1) and the genus Bifidobacterium, pseudocatenulatum species (2) deposited in the DSMZ collection center (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH; Braunsweig, Germany), in accordance with the Treaty of Budapest, on 21 Jul. 2004.
대표청구항
▼
1. A Bifidobacterium strain of folic acid producing probiotic bacteria of human origin selected from the group consisting of: Bifidobacterium adolescentis DSM 16594, Bifidobacterium adolescentis DSM 16595, Bifidobacterium breve DSM 16596, Bifidobacterium pseudocatenulatum DSM 16597, and Bifidobacter
1. A Bifidobacterium strain of folic acid producing probiotic bacteria of human origin selected from the group consisting of: Bifidobacterium adolescentis DSM 16594, Bifidobacterium adolescentis DSM 16595, Bifidobacterium breve DSM 16596, Bifidobacterium pseudocatenulatum DSM 16597, and Bifidobacterium pseudocatenulatum DSM 16598. 2. A Bifidobacterium strain according to claim 1, wherein said strain is Bifidobacterium adolescentis DSM 16594. 3. A Bifidobacterium strain according to claim 1, wherein said strain is Bifidobacterium adolescentis DSM 16595. 4. A Bifidobacterium strain according to claim 1, wherein said strain is Bifidobacterium breve DSM 16596. 5. A Bifidobacterium strain according to claim 1, wherein said strain is Bifidobacterium pseudocatenulatum DSM 16597. 6. A Bifidobacterium strain according to claim 1, wherein said strain is Bifidobacterium pseudocatenulatum DSM 16598. 7. A pharmaceutical, veterinary or food formulation comprising one or more of the Bifidobacterium strains according to claim 1. 8. A formulation according to claim 7, comprising two or more of the strains according to claim 1. 9. A formulation according to claim 7, further comprising one or more probiotic bacterial strains having complementary characteristics, wherein said probiotic bacterial strains are selected from the group consisting of: Lactobacillus acidophilus LMG P-21381;Lactobacillus casei subsp. paracasei LMG P-21380;Lactobacillus plantarum LMG P-21021;Lactobacillus pentosus LMG P-21019;Lactobacillus plantarum LMG P-21020;Lactobacillus plantarum LMG P-21022;Lactobacillus plantarum LMG P-21023;Bifidobacterium lactis LMG P-21384;Streptococcus delbrueckii subsp. thermophilus DSM 16506;Streptococcus delbrueckii subsp. thermophilus DSM 16507;Bifidobacterium longum DSM 16603;Bifidobacterium breve DSM 16604; andLactobacillus casei subsp. rhamnosus DSM 16605. 10. A formulation according to claim 7, further comprising other substances having prebiotic characteristics, wherein said substances having prebiotic characteristics are selected from the group consisting of: fructo-oligosaccharides (FOS), inulin, isomalto-oligosaccharides, resistant starch, pectin, galacto-oligosaccharides, arabinogalactan, xylo-oligosaccharides, glucomannan and chitosan oligosaccharides. 11. A formulation according to claim 9, further comprising other substances having prebiotic characteristics, wherein said substances having prebiotic characteristics are selected from the group consisting of: fructo-oligosaccharides (FOS), inulin, isomalto-oligosaccharides, resistant starch, pectin, galacto-oligosaccharides, arabinogalactan, xylo-oligosaccharides, glucomannan and chitosan oligosaccharides. 12. A formulation according to claim 7, further comprising an additive, a vehicle, an excipient, a flavoring, or a stabilizer, wherein said additive is selected from the group consisting of: amino acids, vitamins, antioxidants, enzymes, glutamine, arginina, superoxide dismutase, and glutathione. 13. A formulation according to claim 7, wherein said one or more strains is present in freeze-dried form. 14. A formulation according to claim 7, containing from 105 to 1011 of cells of said one or more strains per single dose. 15. A formulation according to claim 7, in the form of a capsule, an oral solution or suspension, a powder in a packet, a tablet, a suppository, a vaginal tablet or a pessary. 16. A Bifidobacterium strain according to claim 1, wherein said strain is provided as a probiotic in a food product, or is provided in a product derived from milk or its derivatives, or is provided in combination with a prebiotic substance, or is provided in a symbiotic food preparation.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.